WEBSITE BSE:544319 NSE: SENORES Inc. Year: 2017 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:59
Senores Pharmaceuticals Limited, founded in 2017 and headquartered in Ahmedabad, India, is a rapidly growing pharmaceutical company that specializes in manufacturing a wide range of high-quality pharmaceutical products. The company’s offerings span several therapeutic areas, including antibiotics, antifungals, and critical care medications. With a strong international presence, Senores Pharmaceuticals exports to regulated markets such as the United States, Canada, and the United Kingdom, as well as emerging markets across Africa, the Middle E...Read More
Senores Pharmaceuticals Limited, founded in 2017 and headquartered in Ahmedabad, India, is a rapidly growing pharmaceutical company that specializes in manufacturing a wide range of high-quality pharmaceutical products. The company’s offerings span several therapeutic areas, including antibiotics, antifungals, and critical care medications. With a strong international presence, Senores Pharmaceuticals exports to regulated markets such as the United States, Canada, and the United Kingdom, as well as emerging markets across Africa, the Middle East, and Latin America. The company has made significant strides in its operations, with a portfolio of over 55 products in key therapeutic segments and a growing footprint in 43 countries. Senores Pharmaceuticals has seen remarkable financial growth, with a 157% year-on-year revenue increase and significant expansion in both regulated and emerging markets. Additionally, the company has strategically broadened its reach by launching subsidiaries in key regions, including the United States, and by acquiring majority stakes in various pharmaceutical companies. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹4104 Cr.
Stock P/E 70.3
P/B 4.8
Current Price ₹891.2
Book Value ₹ 184
Face Value 10
52W High ₹944.7
Dividend Yield 0%
52W Low ₹ 474
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 175 |
| Other Income | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 4 |
| Total Income | 80 | 104 | 81 | 102 | 108 | 126 | 141 | 167 | 178 |
| Total Expenditure | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 |
| Operating Profit | 16 | 24 | 22 | 25 | 31 | 31 | 38 | 55 | 58 |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 |
| Provision for Tax | 3 | 3 | 3 | 3 | 4 | 3 | 5 | 11 | 11 |
| Profit After Tax | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 |
| Adjustments | -0 | 2 | -0 | -0 | 1 | -0 | -1 | 2 | -2 |
| Profit After Adjustments | 7 | 16 | 11 | 13 | 17 | 18 | 20 | 32 | 32 |
| Adjusted Earnings Per Share | 2.4 | 5.2 | 3.2 | 3.9 | 3.7 | 3.9 | 4.3 | 7 | 6.9 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 14 | 35 | 215 | 398 | 589 |
| Other Income | 0 | 4 | 3 | 19 | 24 |
| Total Income | 15 | 39 | 217 | 418 | 612 |
| Total Expenditure | 12 | 23 | 173 | 309 | 432 |
| Operating Profit | 2 | 16 | 44 | 109 | 182 |
| Interest | 1 | 2 | 9 | 22 | 21 |
| Depreciation | 1 | 2 | 10 | 17 | 27 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 12 | 25 | 71 | 133 |
| Provision for Tax | 0 | 4 | -8 | 12 | 30 |
| Profit After Tax | 1 | 8 | 33 | 58 | 103 |
| Adjustments | 0 | 0 | -1 | 0 | -1 |
| Profit After Adjustments | 1 | 8 | 31 | 59 | 102 |
| Adjusted Earnings Per Share | 1.1 | 8.6 | 10.3 | 12.7 | 22.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 85% | 205% | 0% | 0% |
| Operating Profit CAGR | 148% | 279% | 0% | 0% |
| PAT CAGR | 76% | 287% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 67% | NA% | NA% | NA% |
| ROE Average | 12% | 20% | 15% | 15% |
| ROCE Average | 12% | 14% | 12% | 12% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 37 | 45 | 204 | 786 |
| Minority's Interest | 0 | 0 | 27 | 26 |
| Borrowings | 12 | 30 | 134 | 162 |
| Other Non-Current Liabilities | 0 | 4 | -6 | -7 |
| Total Current Liabilities | 10 | 52 | 248 | 241 |
| Total Liabilities | 59 | 131 | 607 | 1208 |
| Fixed Assets | 7 | 27 | 235 | 301 |
| Other Non-Current Assets | 25 | 52 | 121 | 185 |
| Total Current Assets | 27 | 51 | 251 | 722 |
| Total Assets | 59 | 131 | 607 | 1208 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 3 | 0 | 8 |
| Cash Flow from Operating Activities | -10 | -1 | -26 | -46 |
| Cash Flow from Investing Activities | -24 | -48 | -54 | -429 |
| Cash Flow from Financing Activities | 36 | 46 | 87 | 573 |
| Net Cash Inflow / Outflow | 2 | -3 | 7 | 98 |
| Closing Cash & Cash Equivalent | 3 | 0 | 8 | 105 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.13 | 8.59 | 10.31 | 12.72 |
| CEPS(Rs) | 1.94 | 10.4 | 14 | 16.33 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 41.86 | 46.36 | 66.95 | 170.72 |
| Core EBITDA Margin(%) | 13.78 | 35.85 | 19.38 | 22.51 |
| EBIT Margin(%) | 12.05 | 41.25 | 16.03 | 23.13 |
| Pre Tax Margin(%) | 8.07 | 35.2 | 11.63 | 17.72 |
| PAT Margin (%) | 6.99 | 23.86 | 15.25 | 14.65 |
| Cash Profit Margin (%) | 11.97 | 28.9 | 19.91 | 18.88 |
| ROA(%) | 1.69 | 8.89 | 8.86 | 6.43 |
| ROE(%) | 2.71 | 20.55 | 26.19 | 11.78 |
| ROCE(%) | 3.36 | 18.56 | 12.31 | 11.94 |
| Receivable days | 505.67 | 215.56 | 114.09 | 108.09 |
| Inventory Days | 76.84 | 31.54 | 34.45 | 43.08 |
| Payable days | 324.2 | 296.18 | 217.67 | 182.04 |
| PER(x) | 0 | 0 | 0 | 45.04 |
| Price/Book(x) | 0 | 0 | 0 | 3.35 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.39 | 1.99 | 1.24 | 6.42 |
| EV/Core EBITDA(x) | 8.18 | 4.31 | 5.99 | 23.47 |
| Net Sales Growth(%) | 0 | 149.38 | 507.07 | 85.65 |
| EBIT Growth(%) | 0 | 753.34 | 135.95 | 167.87 |
| PAT Growth(%) | 0 | 750.96 | 287.88 | 78.36 |
| EPS Growth(%) | 0 | 657.94 | 20.01 | 23.33 |
| Debt/Equity(x) | 0.39 | 1.34 | 1.22 | 0.39 |
| Current Ratio(x) | 2.74 | 0.99 | 1.01 | 3 |
| Quick Ratio(x) | 2.44 | 0.93 | 0.86 | 2.77 |
| Interest Cover(x) | 3.02 | 6.82 | 3.64 | 4.27 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.12 |
| # | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 45.76 | 45.76 | 45.77 | 45.78 | 45.8 | 45.8 | 45.82 |
| FII | 5.51 | 4.25 | 4.17 | 3.67 | 4.28 | 3.35 | 3.64 |
| DII | 16.61 | 11.5 | 9.65 | 9.51 | 8.61 | 9.31 | 9.61 |
| Public | 32.11 | 38.48 | 40.4 | 41.04 | 41.31 | 41.54 | 40.93 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 2.11 | 2.11 | 2.11 | 2.11 | 2.11 | 2.11 | 2.11 |
| FII | 0.25 | 0.2 | 0.19 | 0.17 | 0.2 | 0.15 | 0.17 |
| DII | 0.76 | 0.53 | 0.44 | 0.44 | 0.4 | 0.43 | 0.44 |
| Public | 1.48 | 1.77 | 1.86 | 1.89 | 1.9 | 1.91 | 1.89 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
